DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Marketable Securities

Note 4 - Marketable Securities

3 Months Ended

Mar. 31, 2019

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

4.	Marketable Securities

The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis:

			Fair Value Measurements as of March 31, 2019 Using Inputs Considered as
	Fair Value		Level 1		Level 2		Level 3
Commercial paper and corporate bonds	$	3,978	$	—	$	3,978	$	—
Government securities		6,980		—		6,980		—
Total marketable securities	$	10,958	$	—	$	10,958	$	—

There were

transfers of assets between Level

and Level

of the fair value measurement hierarchy during the quarter ended

March 31, 2019.

Under the terms of the Company’s investment policy, purchases of marketable securities are limited to investment grade governmental and corporate obligations with a primary objective of principal preservation. Maturities of individual securities are less than

one

year and the amortized cost of all securities approximated fair value as of

March 31, 2019.